Deep Dive Ticker Tape
Article published Mar 12, 2026. Prices below use latest available snapshots.
TMO Price Structure
Loading chart…
Loading timeframes…
Conviction: Medium-High Status: Buy — RSI 32.5, price $476.70, in entry zone, continued base-building
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 RSI 32.5 (computed) — approaching oversold. Price $476.70, -3.8% today, -8.1% 7D, -6.5% 30D. SMA20 ~$508.77 — price -6.3% below SMA. SMA gap widening. |
| Moat | Wide (lab equipment, reagents, instruments monopoly) |
| Key insight | TMO declined sharply from $495.61 (03/11) to $476.70 (-3.8%). RSI essentially flat at 32.5 vs 32.9. The base-building has deteriorated into a downtrend. Price now -6.3% below SMA. Still in entry zone ($470-$520) but approaching lower end. Wide moat thesis intact. Buy maintained but acknowledging continued weakness. |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | ✅ Buy (staged) | RSI 32.5 in entry zone, wide moat. Buy in stages. |
| Entry Zone | $465 - $510 | Current $476.70 — IN ZONE (lower end) |
| Stop-Loss | $440 (-8%) | Below multi-year support |
| Target | $650 (+36%) | Recovery toward prior levels |
Extended analysis
Price Data
| Stock | Price | 1D | 7D | 30D | 3M | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|
| TMO | $476.70 | -3.8% | -8.1% | -6.5% | -16.6% | 33 | 🟡 Approaching Oversold | ✅ Buy |
Price vs Last Deep Dive (03/11)
| Metric | 03/11 | 03/12 | Change |
|---|---|---|---|
| Price | $495.61 | $476.70 | -$18.91 (-3.8%) |
| RSI | 32.9 | 32.5 | -0.4 (flat) |
| SMA20 | ~$511.29 | ~$508.77 | -$2.52 (SMA declining) |
| vs SMA | -3.1% | -6.3% | SMA gap doubled |
Update from 03/11: Sharp decline of -3.8% on top of recent weakness. RSI flat at 32.5 while price fell — another positive divergence. SMA gap doubled from -3.1% to -6.3%. Buy thesis intact but entry zone has shifted lower. Accumulate in stages with $440 stop.
Company Overview
One-Liner
Thermo Fisher Scientific is the world's largest life sciences company, providing instruments, reagents, and services to every lab globally.
Competitive Moat
| Moat Type | Present? | Evidence |
|---|---|---|
| Switching costs | 🟢 | Scientific protocols lock in specific instruments/reagents |
| Intangible assets | 🟢 | Brand trust in research |
| Cost advantages | 🟢 | $45B+ revenue = unmatched scale |
| Efficient scale | 🟢 | Only company covering full lab workflow |
Moat Width: Wide
Bull Case
- Essential infrastructure — Every lab needs TMO products.
- RSI 32.5 in entry zone — Approaching oversold on wide moat.
- Bioproduction secular tailwind — mRNA, cell therapy, gene editing.
- Picks-and-shovels for pharma AI — AI drug discovery increases demand.
- RSI flat while price falls — Positive divergence.
Bear Case
- Pharma R&D budget cuts — Largest segment cutting spending.
- Insider selling $323.3M — Among highest in coverage.
- China exposure ~15% — Geopolitical risk.
- SMA gap doubling — Momentum clearly downward.
- -8.1% 7D — Active selling pressure.
Research Log
| Date | Update |
|---|---|
| 2026-02-16 | Created. RSI 5.5 extreme. $504.82. Buy. |
| 2026-02-22 | $510.93 (+1.2%). RSI 19.2. Buy. |
| 2026-02-26 | $515.03. RSI 32.2. Near entry zone top. Buy. |
| 2026-03-03 | $507.81 (-1.4%). RSI 31.2. Consolidation. Buy. |
| 2026-03-10 | $509.97 (+0.4%). RSI 38.4. SMA gap nearly closed. Buy. |
| 2026-03-11 | $495.61 (-2.8%). RSI 32.9. Recovery stalled. SMA gap widened. Buy maintained. |
| 2026-03-12 | $476.70 (-3.8%). RSI 32.5. Sharp decline. SMA gap doubled. Buy in stages. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| RSI flat while price -3.8% | Positive divergence — sellers may be exhausting |
| SMA gap: -3.1% → -6.3% in one day | Sharp deterioration — buy in stages, not all at once |
| Still in entry zone (lower end) | Buy thesis intact but reduce position size given momentum |
Open Questions
- What drove the -3.8% decline? Macro sector rotation?
- Is pharma R&D spending showing signs of recovery?
- Are insider sales on scheduled plans?